Neuroprotection of the preterm brain

Area of Science:

• Neonatal neurology
• Developmental neuroscience
• Pediatric neuroprotection

Background:

• Preterm infants often experience long-term cognitive, behavioral, and motor deficits despite advances in neonatal care.
• Existing neuroprotective strategies are insufficient, highlighting a critical gap in managing these vulnerable neonates.
• Current interventions like magnesium sulfate and caffeine offer limited benefits and variable administration.

Purpose of the Study:

• To review the current challenges and bottlenecks in developing effective neuroprotective strategies for preterm neonates.
• To explore innovative therapeutic avenues and delayed interventions to improve neurodevelopmental outcomes.
• To address the unmet need for robust neuroprotection in fragile preterm infants.

Main Methods:

• Review of current literature on preterm infant neurodevelopmental deficits.
• Analysis of existing and potential neuroprotective agents and their mechanisms.
• Examination of modern epidemiological data, neuroimaging, and experimental models.
• Discussion of bottlenecks hindering progress in the field.

Main Results:

• Significant proportion of preterm neonates suffer from persistent neurodevelopmental impairments.
• Current pharmacological interventions (magnesium sulfate, caffeine) show limited efficacy and inconsistent use.
• There is a clear need for more specific and effective neurotherapeutic strategies.

Conclusions:

• Novel and specific neurotherapeutic strategies are urgently required to enhance outcomes for preterm infants.
• Addressing pathophysiologic mechanisms with modern research approaches is essential.
• Exploring innovative interventions, including delayed strategies, holds promise for improving neuroprotection.